- Home
- WEA vs VXRT Comparison
WEA vs VXRT Comparison
Compare WEA & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- VXRT
- Stock Information
- Founded
- WEA 2002
- VXRT N/A
- Country
- WEA United States
- VXRT United States
- Employees
- WEA N/A
- VXRT N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- VXRT Health Care
- Exchange
- WEA Nasdaq
- VXRT Nasdaq
- Market Cap
- WEA 129.0M
- VXRT 119.0M
- IPO Year
- WEA N/A
- VXRT N/A
- Fundamental
- Price
- WEA $10.61
- VXRT $0.42
- Analyst Decision
- WEA
- VXRT Strong Buy
- Analyst Count
- WEA 0
- VXRT 2
- Target Price
- WEA N/A
- VXRT $3.00
- AVG Volume (30 Days)
- WEA 46.1K
- VXRT 1.4M
- Earning Date
- WEA 01-01-0001
- VXRT 05-13-2025
- Dividend Yield
- WEA 7.87%
- VXRT N/A
- EPS Growth
- WEA N/A
- VXRT N/A
- EPS
- WEA N/A
- VXRT N/A
- Revenue
- WEA N/A
- VXRT $28,700,000.00
- Revenue This Year
- WEA N/A
- VXRT N/A
- Revenue Next Year
- WEA N/A
- VXRT N/A
- P/E Ratio
- WEA N/A
- VXRT N/A
- Revenue Growth
- WEA N/A
- VXRT 288.94
- 52 Week Low
- WEA $9.60
- VXRT $0.28
- 52 Week High
- WEA $11.29
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- WEA 44.92
- VXRT 52.21
- Support Level
- WEA $10.56
- VXRT $0.37
- Resistance Level
- WEA $10.72
- VXRT $0.38
- Average True Range (ATR)
- WEA 0.16
- VXRT 0.04
- MACD
- WEA -0.02
- VXRT 0.01
- Stochastic Oscillator
- WEA 15.22
- VXRT 59.73
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.